DOCSLIB.ORG

Impact Education AMCP Psoriatic Disease Activity.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Impact Education AMCP Psoriatic Disease Activity.Pdf Jointly provided by This activity is supported by Held in conjunction with AMCP Managed independent educational grants from Care & Specialty Pharmacy Annual Meeting Novartis Pharmaceutical Corporation 2018 and Celgene Corporation. Psoriasis Clinical Update: Assessing the Latest Trial Data and Treatment Algorithms Paul S. Yamauchi, MD, PhD Clinical Assistant Professor of Medicine Division of Dermatology, David Geffen School of Medicine University of California, Los Angeles Learning Objectives • Assess current and emerging therapies for the treatment of psoriasis and cite their clinical trial data • Examine alignment of managed care psoriasis treatment algorithms with recent clinical trial data Chronic Plaque Psoriasis: A Multisystem Inflammatory Disease • Chronic relapsing immune‐mediated inflammatory disease • Affects >3% of the US population • Affects multiple areas of the body • Up to 30% of patients with psoriasis develop psoriatic arthritis • Accompanied by significant clinical, social, and economic burden Psoriasis Fact Sheet. National Psoriasis Foundation Web site. https://www.psoriasis.org/sites/default/files/publications/PsoriasisFactSheet.pdf. Published February 2015. Accessed March 2018. About Psoriatic Arthritis. National Psoriasis Foundation Web site. https://www.psoriasis.org/about‐psoriatic‐arthritis. Accessed March 2018. Plaque Psoriasis is the Most Common of the Five Recognized Variants Severity of Plaque Psoriasis • Plaque: scaly, erythematous patches, papules, and plaques that are Mild Moderate Severe sometimes pruritic; affects ~80% of patients • Inverse/flexural: lesions are located in the skin folds • Guttate: small papules with fine scale • Erythrodermic: erythema covering nearly the entire body surface area with varying degrees of scaling <3% of BSA 3% ‐10% of BSA >10% of BSA • Pustular: clinically apparent pustules Psoriasis Fact Sheet. National Psoriasis Foundation Web site. https://www.psoriasis.org/sites/default/files/publications/PsoriasisFactSheet.pdf. Published February 2015. Accessed March 2018. Immunopathogenesis of Chronic Plaque Psoriasis Disease Initiation Disease Maintenance Psoriatic plaque Keratinocyte Environmental trigger activation and proliferation Stressed Stress keratinocytes Angiogenesis Neutrophils Microorganisms IL‐17A Drugs IL‐17F Tc17 Trauma TNF‐α IL‐22 Smoking TNF‐α IL‐6 IL‐2 IL‐1β IFN‐γ PSORS1 Naïve T cell IL‐23R Dermal DC Th17 Activation IL‐12 IL‐12B Th1 Tc1 IL‐17A Th17 Genetic predisposition IL‐17F IL‐23 IL‐22 Th2 Lymph node Th17 TNF‐α Macrophage IL‐6 IL‐1β DC=dendritic cell; PSORS1=psoriasis susceptibiity 1; IL=interleukin; TNF=tumor necrosis factor. Gaspari AA, Tyring S. Dermatol Ther. 2015;28(4):179‐93. Nestle FO, Kaplan DH, Barker J. N Engl J Med. 2009;361(5):496‐509. Individuals with Psoriasis are At Risk of Developing Other Chronic Conditions ↑ risk of poor self‐esteem, Depression/Anxiety psychological stress, and anxiety due to their psoriasis 39% ↑ risk of CV mortality Cardiovascular Disease 70% ↑ risk of MI 56% ↑ risk of MI 346% ↑ risk (mild psoriasis) Obesity 123% ↑ risk (severe) Metabolic Syndrome 22% ↑ risk (mild) 98% ↑ risk (severe) 14% ↑ risk (mild) Diabetes 46% ↑ risk (severe) Ni C, Chiu MW. Clin Cosmet Investig Dermatol. 2014;7:119‐32. Assessing Psoriasis Severity Assessments Classification of Severity Mild disease: <3% BSA Body Surface Area Percentage of skin area involved Moderate disease: 3%–10% BSA (BSA) Severe disease: >10% BSA Lesion characteristics including erythema, scaling, induration Psoriasis Area and Severity Index (PASI) Mild‐to‐moderate disease: Location/distribution of lesions BSA ≤ 10 and PASI ≤ 10 (eg, hands, feet, face, genitals) and DLQI ≤ 10 Dermatology Life Quality Index Moderate‐to‐severe disease: Impact on psychological factors (DLQI) (BSA >10 or PASI >10) and quality of life Itch Severity Score and DLQI >10 (ISS) Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. JAMA Dermatol. 2013;149(10):1180‐5. Menter A, Gottlieb A, Feldman SR, et al. J Am Acad Dermatol. 2008;58(5):826‐50. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten. J Invest Dermatol. 2010;130(4):933‐43. Both H, Essink‐bot ML, Busschbach J, Nijsten T. J Invest Dermatol. 2007;127(12):2726‐39. Mrowietz U, Kragballe K, Reich K, et al. Arch Dermatol Res. 2011;303(1):1‐10. Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Br J Dermatol. 2007;156(4):667‐73. Treatment of Psoriasis: Establish Individualized Treatment Goals • Goals of treatment1 Treatment • Clear the skin AEs • Minimize adverse events • Enhance patient quality of life Tailor • Address comorbidities Therapy Patient Patient Perception • Individualize therapy by involving of Severity the patient in treatment decision‐ making1,2 Disease • Consider patient preferences when Severity selecting therapy1,2 1. Schaarschmidt ML, Schmieder A, Umar N, et al. Arch Dermatol. 2011;147(11):1285‐94. 2. Brezinski EA, Armstrong AW. Semin Cutan Med Surg. 2014;33(2):91‐7. Treatment Approach: Treat‐to‐Target Treatment Goal: Reduce BSA to ≤1% three months after initiating treatment Initiate 3 months 6 months + Treatment post‐initiation post‐initiation Yes No Yes No BSA ≤1% BSA ≤1% Modify therapy Modify therapy Continue • Adjust dose Continue • Adjust dose current • Add another agent current • Add another agent therapy (combination therapy) therapy (combination therapy) • Switch to a new therapy • Switch to a new therapy Armstrong AW, Siegel MP, Bagel J, et al. J Am Acad Dermatol. 2017;76(2):290‐298. Treatment Options for Psoriasis • Topical therapies Mild • Steroid creams • Vitamin D analogues • Vitamin A retinoids • Ultraviolet light/lasers Moderate • UVB • PUVA • Systemic therapies Severe • Traditional/biologic DMARDs Psoriasis Severity Psoriasis Treatments. National Psoriasis Foundation Web site. https://www.psoriasis.org/about‐psoriasis/treatments. Accessed March 2018. Disease Severity Guides Treatment Selection Plaque Signs/symptoms of Yes Systemic psoriasis Phototherapy psoriatic arthritis? pharmacotherapy +/‐ diagnosed No Severity of disease? Mild Moderate‐to‐severe No Topical agents +/‐ Phototherapy Effective? Yes Continue current therapy Menter A, Gottlieb A, Feldman SR, et al. J Am Acad Dermatol. 2008;58(5):826‐50. Menter A, Korman NJ, Elmets CA, et al. J Am Acad Dermatol. 2009;60(4):643‐59. Menter A, Korman NJ, Elmets CA, et al. J Am Acad Dermatol. 2010;62(1):114‐35. Traditional Systemic DMARDS Acitretin Cyclosporine Methotrexate • Vitamin A derivative • Blocks inflammatory • Competitive inhibitor (retinoid) cytokine production of dihydrofolate • Immunomodulatory and T‐cell activation reductase and anti‐inflammatory • Initial approval: 1997 • Interferes with nucleic activity acid synthesis • Modulates epidermal inhibiting lymphoid proliferation and proliferation differentiation • Initial approval: 1972 • Initial approval: 1996 Menter A, Korman NJ, Elmets CA, et al. J Am Acad Dermatol. 2009;61(3):451‐85. Risk‐Benefit Ratios of Traditional DMARDs Efficacy Toxicity Cyclosporine Methotrexate Acitretin Biologics and Small Molecules Approved for the Treatment of Moderate‐to‐Severe Psoriasis Therapeutic Target IL‐17 TNF‐ IL‐17A IL‐23 IL‐12/23 PDE‐4 Receptor Adalimumab Brodalumab Secukinumab Guselkumab Ustekinumab Apremilast Certolizumab Ixekizumab Tildrakizumab Pegol Etanercept Golimumab Infliximab Biosimilars TNF=tumor necrosis factor; IL=interleukin; PDE‐4=phosphodiesterase Treatment Comparison. National Psoriasis Foundation Web site. https://www.psoriasis.org/sites/default/files/treatment_comparison_chart_7.pdf. Published December 2017. Accessed March 2018. Biologics Approved for Moderate‐to‐Severe Chronic Plaque Psoriasis: PASI 75, 90, and 100 Scores 100 PASI 75 PASI 90 PASI 100 90% 90 86% 82% 82% PASI 80 76% 71% 71% 73% 70 64% 59% 58% 59% achieving 60 51% 50 45% 44% 41% 40 36% 35% 75/90/100 33% patients 30% 30 26% of 20% 18% 20 14% 14% 10 7% Percent 0 Methotrexate12 Etanercept Adalimumab 34 Infliximab Ustekinumab 5 Secukinumab 67 Apremilast Ixekizumab8 Brodalumab91011 Guselkumab Tildrakizumab (Week 16) (Week 24) (Week 16) (Week 24) (Week 12) (Week 12) (Week 16) (Week 12) (Week 12) (Week 12) (Week 12) 1. Saurat JH, Stingl G, Dubertret L, et al. Br J Dermatol. 2008;158(3):558‐66. 2. Leonardi CL, Powers JL, Matheson RT, et al. N Engl J Med. 2003;349(21):2014‐22. 3. Menter A, Tyring SK, Gordon K, et al. J Am Acad Dermatol. 2008;58(1):106‐15. 4. Reich K, Nestle FO, Papp K, et al. Lancet. 2005;366(9494):1367‐74. 5. Papp KA, Langley RG, Lebwohl M, et al. Lancet. 2008;371(9625):1675‐84. 6. Langley RG, Elewski BE, Lebwohl M, et al. N Engl J Med. 2014;371(4):326‐38. 7. Otezla (apremilast) [package insert]. Summit, NJ: Celgene Corp.; 2017. 8. Taltz (ixekizumab) [package insert]. Indianapolis, IN: Eli Lilly and Co.; 2018. 9. Siliq (brodalumab) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals; 2017. 10. Tremfya (guselkumab) [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2017. 9.Sun Pharma announces U.S. FDA approval of Ilumya (tildrakizumab‐asmn) for the treatment of moderate‐to‐severe plaque psoriasis. [news release]. Princeton, NJ: Sun Pharma; March 21, 2018. Biologics and Small Molecules in Late‐Stage Development Agent Description/Mechanism Status • Humanized IgG1 monoclonal antibody Risankizumab Phase 3 • Selectively binds the p19 subunit of IL‐23 • Highly selective monoclonal antibody Bimekizumab Phase 3 • IL‐17A and IL‐17F inhibitor • Small molecule A3 adenosine receptor antagonist Piclidenoson • Downregulates the nuclear factor‐ĸB signaling Phase 3 pathway • PEGylated anti‐TNF‐α biologic Certolizumab
Load more

Recommended publications
  • Ixekizumab for the Treatment of Active Psoriatic Arthritis in Adult Patients
    Nº 536 AUGUST /2020 Ixekizumab for the treatment of active psoriatic arthritis in adult patients with an inadequate response or intolerance to one or more disease- modifying antirheumatic drugs (DMARDs) Brasília – DF 2020 Technology: Ixekizumab (Taltz®). Indication: Active psoriatic arthritis (PsA) in adult patients with an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Applicant: Eli Lilly do Brasil LTDA. Background: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis, and also a polygenic autoimmune disorder of unknown etiology, in which cytokines related to T lymphocytes play a key role as in psoriasis. The overall prevalence of PsA ranges from 0.02% to 0.25%, and 1 in 4 patients with psoriasis have psoriatic arthritis: 23.8% (95% confidence interval [CI]: 20.1%-27.6%). In the Brazilian Public Health System (SUS), patients should be provided with access to drug treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs) ibuprofen and naproxen; glucocorticoids prednisone and methylprednisolone; synthetic disease-modifying antirheumatic drugs (DMARDs) sulfasalazine, methotrexate, leflunomide and ciclosporin; biological DMARDs (DMARDs-b) adalimumab, etanercept, infliximab and golimumab; and the cytokine inhibitor anti-IL17 secukinumab. Question: Is ixekizumab effective, safe and cost-effective for the treatment of active psoriatic arthritis (PsA) in adult patients with an inadequate response or intolerance to biological DMARDs? Scientific evidence: A systematic review with a network meta-analysis aimed to investigate the comparative efficacy and safety of interleukin inhibitor class of biologics (IL-6, IL-12/23 and IL-17 inhibitors) for patients with active psoriatic arthritis. Treatment effects were evaluated based on ACR responses (ACR20, ACR50) at week 24; any adverse event (AE); serious adverse events (SAE); and tolerability (discontinuation due to AE), at week 16 or 24.
    [Show full text]
  • New Drug Evaluation Monograph Template
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 OHSU Drug Effectiveness Review Project Summary Report – Targeted Immune Modulators for Autoimmune Conditions Date of Review: October 2020 Date of Last Review: February 2020 Literature Search: 1/1/20 – 6/28/20 Current Status of PDL Class: See Appendix 1. Purpose: New comparative evidence for existing biologics for autoimmune conditions will be reviewed as presented in 3 Drug Effectiveness Review Project (DERP) systematic reviews focused on safety and efficacy of targeted immune modulators (TIMS) to treat ankylosing spondylitis (AS), rheumatoid arthritis (RA), plaque psoriasis (PsO), psoriatic arthritis (PsA), Crohn’s disease (CD), and ulcerative colitis (UC). Research Questions: 1. What is the comparative effectiveness of TIMs for alleviating symptoms and stabilizing disease in patients with RA, AS, PsO, PsA, CD and UC? 2. What are the comparative harms of TIMs when used to treat RA, AS, PsO, PsA, CD, and UC? 3. Do the included drugs differ in their effectiveness or harms in the following subgroups: age and racial groups, gender, patients with comorbidities, patients taking other commonly prescribed drugs, or in patients with early vs. established disease? Conclusions: Targeted Immune Modulators for Rheumatoid Arthritis and Ankylosing Spondylitis Most comparisons for the safety and efficacy of TIMs in RA are limited to single trials.1 Moderate- or high-quality of evidence (QoE) indicates that baricitinib, sarilumab, and upadacitinib are more effective than adalimumab as first-line treatments for RA.1 In a fair-quality, multi-center, double-blind randomized clinical trial (RCT) comparing adalimimumab with baricitinib (n=1,305), adalimumab was less effective than baricitinib for achieving response American College of Rheumatology (ACR) response (ACR20, 61% vs.
    [Show full text]
  • First Analysis of the Severe Paediatric Asthma Collaborative in Europe Registry
    ORIGINAL ARTICLE ASTHMA First analysis of the Severe Paediatric Asthma Collaborative in Europe registry Norrice M. Liu1, Karin C.L. Carlsen2,3, Steve Cunningham4, Grazia Fenu5, Louise J. Fleming 6, Monika Gappa7, Bülent Karadag8, Fabio Midulla9, Laura Petrarca9, Marielle W.H. Pijnenburg10, Tonje Reier-Nilsen3, Niels W. Rutjes11, Franca Rusconi 12 and Jonathan Grigg 1 Affiliations: 1Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, UK. 2Dept of Paediatrics, Faculty of Medicine, University of Oslo, Oslo, Norway. 3Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway. 4Centre for Inflammation Research, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK. 5Paediatrics Pulmonology Unit, Anna Meyer Children’s Hospital, Florence, Italy. 6National Heart and Lung Institute, Imperial College, London, UK. 7Children’s Hospital, Evangelisches Krankenhaus Duesseldorf, Düsseldorf, Germany. 8Division of Pediatric Pulmonology, Marmara University, Istanbul, Turkey. 9Dept of Maternal Science, Sapienza University of Rome, Rome, Italy. 10Dept of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC- Sophia Children’s Hospital, Erasmus University Medical Centre, Rotterdam, The Netherlands. 11Dept of Paediatric Respiratory Medicine, Emma Children’s Hospital/Amsterdam UMC, Amsterdam, The Netherlands. 12Epidemiology Unit, Anna Meyer Children’s University Hospital, Florence, Italy. Correspondence: Jonathan Grigg, Blizard Institute, Queen Mary University of London, London, E1 2AT, UK. E-mail: [email protected] ABSTRACT New biologics are being continually developed for paediatric asthma, but it is unclear whether there are sufficient numbers of children in Europe with severe asthma and poor control to recruit to trials needed for registration. To address these questions, the European Respiratory Society funded the Severe Paediatric Asthma Collaborative in Europe (SPACE), a severe asthma registry.
    [Show full text]
  • Institutional Review Board Informed Consent Document for Research
    Institutional Review Board Informed Consent Document for Research Study Title: PrecISE: Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network Version Date: 11/01/2019 Version: 1.0 Part 1 of 2: MASTER CONSENT Name of participant: __________________________________________ Age: ___________ You are being invited to take part in a research study. This study is a multi-site study, meaning that subjects will be recruited from several different locations. Because this is a multi-site study this consent form includes two parts. Part 1 of this consent form is the Master Consent and includes information that applies to all study sites. Part 2 of the consent form is the Study Site Information and includes information specific to the study site where you are being asked to enroll. Both parts together are the legal consent form and must be provided to you. If you are the legally authorized representative of a person who is being invited to participate in this study, the word “you” in this document refers to the person you represent. As the legally authorized representative, you will be asked to read and sign this document to give permission for the person you represent to participate in this research study. This consent form describes the research study and helps you decide if you want to participate. It provides important information about what you will be asked to do during the study, about the risks and benefits of the study, and about your rights as a research participant. By signing this form, you are agreeing to participate in this study.
    [Show full text]
  • Downloaded Here
    Antibodies to Watch in a Pandemic Dr. Janice M. Reichert, Executive Director, The Antibody Society August 27, 2020 (updated slides) Agenda • US or EU approvals in 2020 • Granted as of late July 2020 • Anticipated by the end of 2020 • Overview of antibody-based COVID-19 interventions in development • Repurposed antibody-based therapeutics that treat symptoms • Newly developed anti-SARS-CoV-2 antibodies • Q&A 2 Number of first approvals for mAbs 10 12 14 16 18 20 Annual first approvals in either the US or EU or US the either in approvals first Annual 0 2 4 6 8 *Estimate based on the number actually approved and those in review as of July 15, with assumption of approval on the first c first the on of approval assumption 15, with as July of review in those and approved actually number the on based *Estimate Tables of approved mAbs and antibodies in review available at at mAbs ofand available in antibodies approved review Tables 1997 98 99 2000 01 02 03 Year of first US or EU approval or EU US of first Year 04 05 06 https://www.antibodysociety.org/resources/approved 07 08 09 10 11 12 13 14 15 Non-cancer Cancer 16 - antibodies/ 17 ycl 18 e. 19 2020* First approvals US or EU in 2020 • Teprotumumab (Tepezza): anti-IGF-1R mAb for thyroid eye disease • FDA approved on January 21 • Eptinezumab (Vyepti): anti-CGRP IgG1 for migraine prevention • FDA approved on February 21 • Isatuximab (Sarclisa): anti-CD38 IgG1 for multiple myeloma • FDA approved on March 2, also approved in the EU on June 2 • Sacituzumab govitecan (Trodelvy): anti-TROP-2 ADC for triple-neg.
    [Show full text]
  • Emerging Therapies in Psoriasis: a Systematic Review
    CLINICAL REVIEW Emerging Therapies In Psoriasis: A Systematic Review Erica B. Lee, BS; Mina Amin, BS; Tina Bhutani, MD; Jashin J. Wu, MD soriasis is a chronic, autoimmune-mediated disease PRACTICE POINTS estimated to affect 2.8% of the US population.1 The pathogenesis of psoriasis is thought to involve a • Tumor necrosis factor α, I L-23, and IL-17A are key P targets for psoriasis therapy based on an under- complex process triggered by a combination of genetic standing of the key role that these cytokines play and environmental factors that induce tumor necrosis in the pathophysiology of disease. factor (TNF) α secretion by keratinocytes, which in turn • The biologic agents secukinumab and ixekizumab activates dendritic cells. Activated dendritic cells produce 2,3 are approved for use in the management of pso- IL-23, leading to helper T cell (TH17) differentiation. riasis. Other biologics—brodalumab, bimekizumab, TH17 cells secrete IL-17A, which has been shown to pro- guselkumab, tildrakizumab, risankizumab, and cer- mote psoriatic skincopy changes.4 Therefore, TNF-α, IL-23, tolizumab pegol—have been (and some continue to and IL-17A have been recognized as key targets for pso- be) the focus of phase 2 and phase 3 clinical trials. riasis therapy. • Findings of several of those trials support the idea that The newest biologic agents targeting IL-17– therapies targeting IL-23, specifically its p19 subunit, mediated pathways include ixekizumab, brodalumab, but that spare IL-12 are effective against psoriasis. andnot bimekizumab. Secukinumab, the first US Food and • Longer-term studies are needed to determine whether Drug Administration (FDA)–approved IL-17 inhibitor, the agents reviewed here, including those approved for has been available since 2015 and therefore is not clinical use, are suitable for prolonged administration.
    [Show full text]
  • Bimzelx, INN-Bimekizumab
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Bimzelx 160 mg solution for injection in pre-filled syringe Bimzelx 160 mg solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Bimzelx 160 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 160 mg of bimekizumab in 1 mL. Bimzelx 160 mg solution for injection in pre-filled pen Each pre-filled pen contains 160 mg of bimekizumab in 1 mL. Bimekizumab is a humanised IgG1monoclonal antibody produced in a genetically engineered Chinese hamster ovary (CHO) cell line by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection) The solution is clear to slightly opalescent and pale brownish-yellow. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. 4.2 Posology and method of administration Bimzelx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of plaque psoriasis. Posology The recommended dose for adult patients with plaque psoriasis is 320 mg (given as 2 subcutaneous injections of 160 mg each) at week 0, 4, 8, 12, 16 and every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who have shown no improvement by 16 weeks of treatment.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Gist Right: Five Leading Dermatologists Balance Education and Engagement in New Web Series
    PRACTICAL DERMATOLOGY® NEWS << VOLUME 16, NO. 11 • NOVEMBER 2019 Gist Right: Five Leading Dermatologists Balance Education and Engagement in New Web Series Five leading dermatologists are taking on social >> media misinformation one YouTube video at a time. Doris Day, MD; Jeanine Downie, MD; Sabrina Fabi, MD; Ava Shamban, MD; and Ruth Tedaldi, MD are the faces—and the brains—of “The Gist,” a new web series aimed at giving dermatology patients the facts about aesthetic and medical conditions and treatments. “We were constantly seeing lots of social media presence that is not accurate or expert in nature. We talk about it all the time,” says Dr. Tedaldi. The physicians wanted to find a way to reach the masses with facts and science, rather than hype. The concept of a web-based discussion format program was born. “We were very motivated and very excited,” Dr. Tedaldi says. “Really what we want to do is open the field of aes- thetic medicine.” “We want to take the fright factor out of cosmetic derma- benefit of having not just one opinion; you have the five tology,” adds Dr. Downie. opinions. It’s very difficult to go see even one dermatologist, The team knew that producing the series would require but to be able to have access to five very educated derma- more resources than they could muster. They approached tologists?” Allergan, and the company agreed to support the program The panelists may not always reach consensus, but viewers to grow the market for everyone as a non-branded venue. “can find the truth somewhere in between,” Dr.
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]